After years of being told their crushing exhaustion might be “all in their head,” people with Myalgic ...

On Tuesday, Coya Therapeutics, Inc. (NASDAQ:COYA) released results from the placebo-controlled Phase 2 trial of LD IL-2 in patients with mild to moderate Alzheimer’s Disease. The data was shared at ...

"Boosting the immune defense: Interleukin-2 promotes fate decisions in CD8 T cells for long- or short-term immune protection." ScienceDaily. www.sciencedaily.com / releases / 2022 / 02 / ...

Immatics is advancing Anzu-cel, a T-cell receptor therapy for melanoma with potential for significant annual revenue. Learn ...

BARCELONA, Spain--(BUSINESS WIRE)--Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I study evaluating the safety, ...

Interleukin-2 (IL-2) is a vital cytokine in adoptive cell therapy that plays an important part in the stimulation and growth of immune cells as well as Tumor-Infiltrating Lymphocytes (TIL), Chimeric ...

Among the many challenges in treating tumors is the difficulty in getting anti-cancer drugs to the right locations, and in the right amounts. A new type of implant developed at Rice University tackles ...

Bonum Therapeutics will occupy the 11th floor of 1150 Eastlake Avenue East at the Alexandria Center for Life Science – Eastlake mega campus. (Photo courtesy of Alexandria Real Estate Equities) Bonum ...

A study in the journal Science Immunology now shows how two subsets of one type of immune cell — the CD8 T cell — develop to provide either short-term or long-term immune protection. The study focuses ...